Two ways scientists can work around limited government funding are (1) repurpose existing secondary data and public research infrastructure so the largest costs are never incurred, and (2) form a consortium with in-kind cost-sharing and shared instrumentation, so each partner contributes equipment, time, or samples rather than cash. Both approaches reduce total spend while leaving the study design intact. What follows shows how each is executed in practice, what the failure modes look like, and roughly what each saves relative to a conventional single-institution study.
The reader here is likely a principal investigator, lab manager, or research administrator staring at an award that covers a fraction of the original protocol. The question is practical: what do you actually do on Monday. The two workarounds below are not theoretical. Each has a documented cost structure, an administrative trail, and a known set of ways it goes wrong.
The key boundary: these workarounds preserve research quality only if the substitution is disclosed and the analysis is pre-specified against the new data source. Repurposing data to fit a hypothesis after the fact is a misconduct risk, not a savings strategy.
Why the Funding Gap Is Structural, Not a One-Off Shortfall
Government science budgets are chronically misaligned with the true cost of studies. The U.S. National Institutes of Health reports that its own success rates for research project grants hovered around 20 percent for much of the past decade, and when a grant is awarded it is frequently at a level below the amount requested. According to NIH's biennial Reports on the Extramural Research Community, average award values have been trimmed relative to investigator-requested budgets in multiple cycles.
That means the shortfall isn't a sign of a badly written proposal. It's the normal case. Scientists who treat it as an anomaly keep proposing full-cost studies and keep running short in month fourteen.
The smarter frame is that government awards buy a portion of a study, and the remainder is assembled from other resources. Experienced investigators build the study in modular pieces so that a partial award still produces publishable output. That modularity is the foundation for both workarounds below.
Workaround One: Repurpose Secondary Data and Public Infrastructure
The single largest line in most studies is primary data collection: recruiting participants, running instruments, paying field staff. Secondary data analysis eliminates that line almost entirely. Public repositories now hold data at a scale no single lab could afford to generate.
The UK Biobank, for instance, holds deep phenotypic and genetic data on roughly 500,000 participants and grants access to approved researchers for a modest application fee. The U.S. National Center for Health Statistics runs the National Health and Nutrition Examination Survey (NHANES) and makes its datasets freely downloadable, with in-person examination data collected on tens of thousands of participants per cycle. ICPSR at the University of Michigan archives social science data across hundreds of studies.
The cost structure is what makes this workaround compelling. A typical epidemiological field study with primary recruitment of several hundred participants can run into the hundreds of thousands of dollars once staff time, participant compensation, and instrument use are counted. Access to a major biobank dataset is usually in the low thousands. The difference is not marginal.
Step-by-step execution:
1: Search the relevant repository (UK Biobank, NHANES, ICPSR, dbGaP for genomic data) for a dataset that matches your exposure and outcome variables; verify variable definitions against the codebook before committing. 2: Download or apply for access β dbGaP and UK Biobank require a data access request reviewed by their committees, which can take 4β12 weeks. 3: Pre-register your analysis plan on a public registry or with your institutional review board before touching the data, so the repurposing is transparent. 4: Run a power calculation against the actual sample size available in the dataset, not your original target. 5: Document the data version and access date in the methods section, because public datasets are re-released and results can shift between versions.
Failure handling: If the dataset lacks a variable you need, do not construct a proxy silently β report the proxy and its validation status. If access is denied, escalate to the data custodian's help desk before abandoning the design; many rejections stem from an incomplete data use agreement, not eligibility.
The weakness of secondary data is control. You cannot add a measurement question mid-study. If the original hypothesis requires a variable that isn't there, this workaround doesn't fit, and no amount of cleverness fixes it.
Workaround Two: Consortium Cost-Sharing and In-Kind Contributions
Where repurposing isn't possible β a clinical trial, a new instrument development, a field campaign β the second workaround is to spread costs across partners who contribute in kind. A university with a suitable instrument lets your team use it in exchange for co-authorship. A partner institution in a different region collects samples at its own expense. A national lab provides compute hours against a shared grant.
The mechanism has real administrative infrastructure. The European Commission's Horizon Europe program built consortia into its core funding model, requiring multi-country partnerships precisely to pool resources. In the U.S., the NSF's Industry-University Cooperative Research Centers program formalizes exactly this logic: member firms and universities co-fund research and share facilities.
Comparison of the two workarounds:
| Dimension | Secondary Data Repurposing | Consortium Cost-Sharing |
|---|---|---|
| Typical lead time to first data | 4β12 weeks (access review) | 8β20 weeks (partnership agreements) |
| Cash required | Low β access fee usually in the low thousands | Low to moderate β each partner funds its share |
| Control over measurements | None | Shared, negotiated in the agreement |
| Administrative burden | Data use agreement, IRB amendment | Consortium agreement, IP terms, scheduling |
| Best suited to | Observational studies, epidemiology, reanalysis | Trials, field work, instrument-dependent research |
| Main failure mode | Missing variable | Partner withdrawal or schedule slip |
The verdict is split. Repurposing fits observational questions with existing datasets β use it when your hypothesis can be tested against variables already collected. Consortium cost-sharing fits studies that need new measurement β use it when the science requires fresh data and the cost must be distributed.
Failure handling: When a partner withdraws, the consortium agreement should specify what happens to data already collected and who retains access. Without that clause, a single withdrawal can halt the study.
What Each Workaround Actually Saves: A Worked Comparison
Numbers make the choice concrete. Take a hypothetical observational study comparing metabolic markers across 2,000 participants. A primary-collection design with recruitment, phlebotomy, and lab assays might reasonably cost several hundred thousand dollars over two years, with the largest shares going to personnel and participant compensation.
The same question answered with an existing biobank cohort might require only the access fee, analyst time, and a statistician's hours. Access fees for major biobanks typically fall in the low-to-mid thousands. Analyst time for a well-scoped secondary analysis might be six months of one postdoctoral researcher's effort.
The savings aren't automatic, though. Secondary analysis carries a hidden cost: the time spent cleaning and harmonizing someone else's data, which can run longer than collecting your own clean data. Estimates vary widely, and I won't invent a figure β verify against your own past project timelines.
For the consortium route, the arithmetic runs differently. Costs are shared rather than eliminated. If four partners each contribute 25 percent of a budget, total spend is unchanged but each institution's cash burden drops accordingly. The strain shifts from fundraising to coordination.
Recruiting Collaborators Without Paying Them: The In-Kind Ledger
Scientists often assume a collaborator must be paid. Not so. Collaborators contribute equipment, samples, staff time, or access, and the value flows both ways through authorship and shared publication credit. The key is transparent accounting.
Maintain an in-kind ledger. List each partner's contribution, its estimated fair value, and the person responsible for delivering it. Circulate it quarterly. This does two things: it prevents disputes about who did what, and it gives your institution's research office something concrete to report to the funder when questions arise about matching contributions.
Funders increasingly accept in-kind contributions as part of cost-share requirements. Always check the specific award terms, because the rules differ by agency and program.
Administrative Guardrails: What Must Be Disclosed
Both workarounds carry compliance obligations that an investigator under funding pressure tends to underestimate. Repurposed data must be disclosed in the methods, including the dataset version, access date, and any variables you constructed. Consortium contributions must be documented in the agreement and reported to the funder.
Institutional review boards frequently require an amendment even for secondary data if the original consent didn't cover the new use. Get the amendment before you analyze, not after.
The general principle is that the funder must be able to reconstruct how the study was actually done from what you report. Anything that obscures that reconstruction is a problem regardless of how honest your intentions are.
When Neither Workaround Fits: Scope Reduction and Staged Studies
Some studies genuinely cannot be done with either approach. A novel intervention with no existing data and no willing partners falls into this category. The honest answer is to reduce scope or stage the study over multiple funding cycles.
Stage one might be a pilot with a small sample that generates preliminary data strong enough to support a larger award. The pilot costs less, can often be funded by internal institutional seed grants or small foundation awards, and produces the feasibility evidence reviewers want. NIH's own funding mechanism structure includes exploratory and pilot grant categories designed for exactly this purpose.
Reducing scope is uncomfortable but defensible if it's disclosed. Promising a 2,000-participant study and delivering 400 without explaining why is not.
The Failure Case: What Happens When the Workaround Is Discovered Late
A frequent and costly error is discovering mid-study that the workaround doesn't hold. The dataset you selected lost a key variable in a version update. The partner who promised instrument time has a scheduling conflict. The IRB rejects the repurposing because consent didn't cover it.
The mitigation is a verification checkpoint before spending any money. Confirm access in writing. Confirm the variable exists in the current version. Confirm the IRB's position in writing. This checkpoint costs a few weeks and a few emails. Skipping it can cost a study.
FAQ
How long does UK Biobank access approval usually take?
UK Biobank's application process typically takes several weeks to a few months, depending on completeness of the application and the scope of data requested. The fee structure varies by data type and project scope, so confirm current fees on the UK Biobank website before budgeting. Applicants should have their institutional sign-off prepared in advance, because delays usually come from missing institutional approvals rather than from the review committee itself.
Can secondary data analysis be published in the same journals as primary studies?
Yes. Major journals in epidemiology and public health regularly publish secondary analyses, provided the methods section clearly identifies the source dataset, access date, and version. The main editorial concern is transparency about prior publications using the same dataset, so check whether the dataset has a publication log or committee and follow its rules.
What's the difference between a consortium and a subcontract?
A consortium is a partnership of equals, each contributing resources and sharing governance under a consortium agreement. A subcontract is a hierarchical arrangement where one institution pays another to perform specified work. Consortium arrangements generally carry more negotiation overhead but avoid cash transfers, which matters when the goal is to reduce spending rather than reallocate it.
Do funders penalize scientists for using existing data instead of collecting new data?
Generally no, provided the choice is justified in the proposal. Many funders actively encourage secondary analysis because it's efficient. The penalty comes from failing to disclose the source or from claiming novelty for an analysis the dataset's publication committee has already approved in a similar form.
What happens if a consortium partner leaves mid-study?
The outcome depends entirely on the consortium agreement's exit clause. Well-drafted agreements specify data custody, publication rights, and financial obligations on withdrawal. If the clause is missing, the remaining partners may need to renegotiate, which can delay the study substantially. Draft the exit clause at the start, not when a partner signals they're leaving.
Can in-kind contributions count toward a funder's cost-share requirement?
Sometimes, but the rules vary by agency and program. Some U.S. federal programs require documented cost-share, while others prohibit it. Read the specific notice of funding opportunity rather than assuming. When in-kind contributions are allowed, they must be documented at fair value and reported through the institution's research office.
Is it acceptable to switch from primary collection to secondary data after the grant is awarded?
It depends on the terms of the award and your institution's policies. A scope change of that magnitude usually requires prior approval from the program officer. Present it as a design adaptation with a justification, not as a quiet substitution, and document the approval in your files.
The material above describes general research administration practice and is not legal, financial, or compliance advice for any specific award. Funding terms, data access rules, and cost-share policies change and differ by agency, institution, and jurisdiction. Confirm every requirement with your institution's sponsored research office and the funding agency's current published terms before acting.